Skip to content
| Chemical Formula | C₂₀₃H₃₁₆N₅₂O₃₇ |
| Molecular Mass | ~4493.3 Da |
| CAS Number | 1405-99-6 |
| Form | Lyophilized peptide powder |
| Shelf Life | 24 months (lyophilized) |
| Intended Use | For preclinical and in vitro research only |
| Storage | -20 °C (dry powder), -80 °C (after reconstitution) |
LL-37 – 5mg
$ 45.00
All products are for laboratory research purposes only. Not for human consumption, medical, or veterinary use. Novara Peptides does not condone or support the use of peptides outside of controlled scientific research. By purchasing, you acknowledge that you are a qualified researcher or institution. You must be 21 or older
Out of stock
LL-37 (Human Cathelicidin Antimicrobial Peptide)
Research-Grade Host Defense Peptide
Tagline: Innate Immunity & Wound Healing Research
Product Description
LL-37 is the only known human cathelicidin-derived antimicrobial peptide, consisting of 37 amino acids. It is a key effector molecule of the innate immune system, with potent broad-spectrum antimicrobial activity against bacteria, viruses, and fungi, as well as immunomodulatory properties.
Researchers use LL-37 in preclinical studies to explore host-pathogen interactions, epithelial barrier defense, wound healing, and inflammatory signaling pathways. Its dual role as an antimicrobial agent and immune modulator makes it an essential tool in infectious disease, dermatology, and immunology research.
For Laboratory and Scientific Research Use Only. Not for Human Consumption.
Why Researchers Choose LL-37
Broad-Spectrum Antimicrobial: Effective against Gram-positive and Gram-negative bacteria, fungi, and some viruses.
Immunomodulatory Activity: Regulates cytokine production and modulates inflammation.
Barrier Function Support: Promotes epithelial cell migration and wound closure in models.
Endogenous Relevance: Derived from human cathelicidin (hCAP18), providing physiological translational value.
Batch Verified: ≥98% purity confirmed by HPLC and mass spectrometry for reproducibility.
Important Note
For laboratory and scientific research only. Not for human consumption, therapeutic, or diagnostic use.
Research Applications
Antimicrobial Activity Studies
LL-37 exhibits direct antimicrobial effects by disrupting microbial membranes, making it key in innate immunity research [1].
Immunology & Cytokine Modulation
Regulates expression of pro- and anti-inflammatory cytokines, helping explore immune balance in infection and autoimmunity [2].
Wound Healing & Tissue Regeneration
Promotes keratinocyte migration, angiogenesis, and tissue repair in wound models [3].
Biofilm & Pathogen Studies
Shown to inhibit biofilm formation and enhance bacterial clearance, supporting research on drug-resistant pathogens [4].
References
Dürr UH et al. (2006). The Human Cathelicidin LL-37: Structure, Function and Clinical Perspectives. Biochem Biophys Res Commun.
https://www.sciencedirect.com/science/article/pii/S0006291X05025061Mookherjee N et al. (2006). Modulation of the Innate Immune Response by LL-37. Nat Rev Immunol.
https://pubmed.ncbi.nlm.nih.gov/17063185/Heilborn JD et al. (2003). Antimicrobial Protein hCAP18/LL-37 Is Involved in Normal Wound Healing. J Invest Dermatol.
https://www.sciencedirect.com/science/article/pii/S0022202X15305785Overhage J et al. (2008). Human Host Defense Peptide LL-37 Prevents Biofilm Formation. Infect Immun.
https://journals.asm.org/doi/full/10.1128/iai.00318-08
Mechanism of Action (How LL-37 Works)
Membrane Disruption: Inserts into microbial membranes, forming pores that cause lysis [Dürr 2006].
TLR Modulation: Interacts with Toll-like receptors (TLR2, TLR4) to fine-tune innate immune responses [Mookherjee 2006].
Chemotactic Activity: Attracts immune cells (neutrophils, monocytes, T cells) to infection sites [Mookherjee 2006].
Wound Healing Promotion: Stimulates keratinocyte proliferation and angiogenesis via growth factor pathways [Heilborn 2003].
Biofilm Inhibition: Prevents bacterial surface attachment and biofilm development [Overhage 2008].
References
Dürr UH et al. (2006). The Human Cathelicidin LL-37: Structure, Function and Clinical Perspectives. Biochem Biophys Res Commun.
https://www.sciencedirect.com/science/article/pii/S0006291X05025061Mookherjee N et al. (2006). Modulation of the Innate Immune Response by LL-37. Nat Rev Immunol.
https://pubmed.ncbi.nlm.nih.gov/17063185/Heilborn JD et al. (2003). Antimicrobial Protein hCAP18/LL-37 Is Involved in Normal Wound Healing. J Invest Dermatol.
https://www.sciencedirect.com/science/article/pii/S0022202X15305785Overhage J et al. (2008). Human Host Defense Peptide LL-37 Prevents Biofilm Formation. Infect Immun.
https://journals.asm.org/doi/full/10.1128/iai.00318-08
